AbbVie Inc
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various c… Read more
AbbVie Inc (ABBV) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: -1.616x
Based on the latest financial reports, AbbVie Inc (ABBV) has a cash flow conversion efficiency ratio of -1.616x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($5.22 Billion) by net assets ($-3.23 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AbbVie Inc - Cash Flow Conversion Efficiency Trend (2010–2025)
This chart illustrates how AbbVie Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AbbVie Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AbbVie Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Netflix Inc
NASDAQ:NFLX
|
0.079x |
|
China Yangtze Power Co. Ltd. GDR
LSE:CYPC
|
0.080x |
|
Costco Wholesale Corp
NASDAQ:COST
|
0.155x |
|
Mastercard Inc
NYSE:MA
|
0.715x |
|
Tencent Holdings Ltd
PINK:TCTZF
|
0.059x |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
0.009x |
|
Fomento Económico Mexicano, S.A.B. de C.V.
LSE:0TD7
|
N/A |
|
Industrial and Commercial Bank of China
PINK:IDCBY
|
-0.001x |
Annual Cash Flow Conversion Efficiency for AbbVie Inc (2010–2025)
The table below shows the annual cash flow conversion efficiency of AbbVie Inc from 2010 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-3.23 Billion | $19.03 Billion | -5.895x | -205.45% |
| 2024-12-31 | $3.36 Billion | $18.81 Billion | 5.590x | +154.49% |
| 2023-12-31 | $10.40 Billion | $22.84 Billion | 2.197x | +52.24% |
| 2022-12-31 | $17.29 Billion | $24.94 Billion | 1.443x | -2.22% |
| 2021-12-31 | $15.44 Billion | $22.78 Billion | 1.476x | +9.88% |
| 2020-12-31 | $13.10 Billion | $17.59 Billion | 1.343x | +182.36% |
| 2019-12-31 | $-8.17 Billion | $13.32 Billion | -1.630x | -2.56% |
| 2018-12-31 | $-8.45 Billion | $13.43 Billion | -1.590x | -181.35% |
| 2017-12-31 | $5.10 Billion | $9.96 Billion | 1.954x | +28.66% |
| 2016-12-31 | $4.64 Billion | $7.04 Billion | 1.519x | -20.48% |
| 2015-12-31 | $3.94 Billion | $7.54 Billion | 1.910x | -6.25% |
| 2014-12-31 | $1.74 Billion | $3.55 Billion | 2.037x | +46.03% |
| 2013-12-31 | $4.49 Billion | $6.27 Billion | 1.395x | -26.05% |
| 2012-12-31 | $3.36 Billion | $6.34 Billion | 1.887x | +260.37% |
| 2011-12-31 | $11.93 Billion | $6.25 Billion | 0.524x | +65.22% |
| 2010-12-31 | $15.70 Billion | $4.98 Billion | 0.317x | -- |